A Degarelix Trial in Patients With Prostate Cancer
Launched by FERRING PHARMACEUTICALS · Nov 16, 2010
Trial Information
Current as of June 07, 2025
Terminated
Keywords
ClinConnect Summary
CS35A was an open-label, multicentre, comparative non-inferiority extension trial to the Phase 3 CS35 trial (NCT00946920).
In the main CS35 trial, participants were randomised 2:1 to treatment with degarelix or goserelin, respectively. All participants who completed the main CS35 trial after initiation of the CS35A trial were eligible to enrol into this extension trial, provided that their treatment could continue uninterrupted. Patients entering the CS35A trial continued with the same 3-monthly treatment as they received in CS35 (i.e. degarelix 480 mg or goserelin 10.8 mg).
It was intend...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Has given written consent prior to any trial-related activity is performed. (A trial-related activity is defined as any procedure that would not have been performed during the normal management of the patient).
- • Has completed the CS35 trial.
- Exclusion Criteria:
- • Has been withdrawn from the CS35 trial.
- • Has had end of trial visit in CS35 prior to approval of the CS35A protocol.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs in various therapeutic areas, including reproductive health, urology, and gastrointestinal disorders. With a strong commitment to advancing healthcare through scientific excellence and patient-centered solutions, Ferring leverages its extensive expertise in hormone-related treatments and personalized medicine. The company actively engages in clinical research to develop safe and effective therapies, striving to improve the quality of life for patients worldwide while maintaining a focus on ethical practices and collaboration in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dnipropetrovsk, , Ukraine
Ipswich, , United Kingdom
Eindhoven, , Netherlands
Aventura, Florida, United States
Burien, Washington, United States
Brno, , Czech Republic
Jindrichuv Hradec, , Czech Republic
Budapest, , Hungary
Miskolc, , Hungary
Miskolc, , Hungary
Pécs, , Hungary
Chihuahua, Chih., , Mexico
Zapopan, Jalisco, , Mexico
Constanta, , Romania
Sibiu, , Romania
Kharkiv, , Ukraine
Kyiv, , Ukraine
Szeged, , Hungary
Bucharest, , Romania
Oulu, , Finland
Budapest, , Hungary
Denver, Colorado, United States
Myrtle Beach, South Carolina, United States
Dover, Delaware, United States
Albuquerque, New Mexico, United States
Kortrijk, , Belgium
Kromeriz, , Czech Republic
Zlin, , Czech Republic
Tampere, , Finland
Nürtingen, , Germany
Budapest, , Hungary
Vác, , Hungary
Den Haag, , Netherlands
Bialystok, , Poland
Bielsko Biala, , Poland
Slupsk, , Poland
Brasov, , Romania
Bucharest, , Romania
Pitesti, , Romania
Donetsk, , Ukraine
Odesa, , Ukraine
Zaporizhzhya, , Ukraine
Sutton, , United Kingdom
Aurora, Colorado, United States
San Antonio, Texas, United States
Brampton, Ontario, Canada
Kelowna, , Canada
Newmarket, , Canada
Scarborough, , Canada
Toronto, , Canada
Praha, , Czech Republic
Praha, , Czech Republic
Tampere, , Finland
Kirchheim, , Germany
Dombóvár, , Hungary
Culiacan, Sinaloa, , Mexico
Durango, , Mexico
Mexico City, Df, , Mexico
Mexico City, , Mexico
Arad, , Romania
Bucharest, , Romania
Bucharest, , Romania
Iasi, , Romania
Patients applied
Trial Officials
Clinical Development Support
Study Director
Ferring Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials